10-Q quarterly report · filed Nov 4, 2026

CYTOKINETICS INC (CYTK) Q3 2026 10-Q Quarterly Report

Short answer

CYTOKINETICS INC (CYTK) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $48M (up 2356.5% year over year) with net income of −$190M.

Q3 2026 key financials · XBRL

Revenue
$48M
+2356.5% YoY · +66.1% QoQ
Net income
−$190M
+37.9% YoY · +4.4% QoQ
Operating margin
-351.3%
EPS (diluted)
−$1.35
+47.1% YoY · +10.0% QoQ

Source: XBRL data from the CYTOKINETICS INC (CYTK) Q3 2026 10-Q on SEC EDGAR. USD.

CYTOKINETICS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $47.6M, up $45.6M YoY, driven by MYQORZO product revenue of $44.5M
  • Q3 operating expenses $214.6M, up $46.0M YoY, including SG&A of $113.1M
  • Best-performing product line: MYQORZO U.S. revenue $43.1M, Europe $1.4M
  • Cash, cash equivalents and securities $1.58B, up from $1.22B at December 31, 2025
  • Nine-month operating cash outflow $429.3M, financing inflow $805.4M including $760.1M public-offering proceeds

Risk Factors

  • New regulatory risk: August 2026 ACACIA-HCM results may not support aficamten approval for nHCM
  • Most material update: Planned supplemental NDA submission in fourth quarter 2026 after positive dual primary endpoints
  • FDA review risk: Left ventricular ejection fraction below 50% occurred more frequently with aficamten
  • Competitive risk: Camzyos failed both dual primary endpoints in ODYSSEY-HCM for nHCM
  • Commercial risk: Delayed or limited approval could prevent nHCM commercialization on the anticipated timeline

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CYTOKINETICS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.